Similar Search Results

Product Innovations, Price Indices and the (Mis)Measurement of Economic Performance

Trajtenberg, Manuel - 1990

The goal of this paper is to address the problem of 'product innovations' (i.e. new goods. increased variety, and quality change) in the construction of price indices and, by extension, in the measurement of economic performance. The premise is that a great deal of technical progress takes the...

Persistent link: https://www.econbiz.de/10012475776

Evaluation of Medical Technologies with Uncertain Benefits

Lakdawalla, Darius N. - 2019

Cost-effectiveness analysis (CEA) remains the de-facto method of choice to evaluate and compare medical interventions. Standard approaches to CEA use the average (mean) outcomes from clinical effectiveness studies such as randomized controlled trials. This paper generalizes standard methods to...

Persistent link: https://www.econbiz.de/10012480006

Advances in Cost-Effectiveness Analysis of Health Interventions

Garber, Alan M. - 1999

The growing application of cost-effectiveness (CE) analysis and controversies about its methods has led to a need to explore its welfare economic foundations. Examination of its welfare theoretic foundations can provide a rationale for selecting specific standards for the application of CE...

Persistent link: https://www.econbiz.de/10012471590

Cost-Effective Policies to Reduce Vehicle Emissions

Fullerton, Don - 2005

This paper uses an estimated demand system that accounts for heterogeneity to calculate and compare the lost consumer surplus from a higher tax on gasoline, a tax on distance, or a subsidy for buying a newer car. We introduce a view of cost-effectiveness that compares policies instead of...

Persistent link: https://www.econbiz.de/10012467511

Hedonic Analysis of Arthritis Drugs

Cockburn, Iain M. - 1998

We examine the relationship between quality'' and market outcomes for a group of drugs used to treat rheumatoid arthritis. Though this is a widespread and debilitating disease with very substantial impacts on the health of patients and on the economy, currently available drugs have limited...

Persistent link: https://www.econbiz.de/10012472235

The Cost-Effectiveness of Alternative Instruments for Environmental Protection in a Second-Best Setting

Goulder, Lawrence H. - 1998

This paper uses analytical and numerical general equilibrium models to study the costs of achieving pollution reductions under a range of environmental policy instruments in a second-best setting with pre-existing factor taxes. We compare the costs and efficiency impacts of emissions taxes,...

Persistent link: https://www.econbiz.de/10012472341

Accounting for Future Costs in Medical Cost-Effectiveness Analysis

Meltzer, David - 1997

Most medical cost-effectiveness analyses include future costs only for related illnesses but this approach is controversial. This paper demonstrates that cost-effectiveness analysis is consistent with lifetime utility maximization only if it includes all future medical and non-medical...

Persistent link: https://www.econbiz.de/10012472878

Leakage, Welfare, and Cost-Effectiveness of Carbon Policy

Baylis, Kathy - 2013

We extend the model of Fullerton, Karney, and Baylis (2012 working paper) to explore cost-effectiveness of unilateral climate policy in the presence of leakage. We ignore the welfare gain from reducing greenhouse gas emissions and focus on the welfare cost of the emissions tax or permit scheme....

Persistent link: https://www.econbiz.de/10012459763

The Economics of Medical Procedure Innovation

Dranove, David; Garthwaite, Craig; Heard, R. Christopher; … - National Bureau of Economic Research - 2021

This paper explores the economic incentives for medical procedure innovation. Using a proprietary dataset on billing … code applications for emerging medical procedures, we highlight two mechanisms that could hinder innovation. First, the … administrative hurdle of securing permanent, reimbursable billing codes substantially delays innovation diffusion. We find that …

Persistent link: https://www.econbiz.de/10012660115

Firm Scope and Spillovers from New Product Innovation : Evidence from Medical Devices

Grennan, Matthew - 2018

policy, due to their potential to foreclose competition and affect innovation incentives. We exploit major new product …

Persistent link: https://www.econbiz.de/10012480835

1
2
3
4
5
6
7
8
9
10
Next
Last